ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Estradiol

Also written as “NOMAC-E2”, “estradiol, 25 mcg” and “estradiol, 10 mcg”.

Its studies are mostly in Hot Flashes · Dyspareunia · Atrophic Vaginitis · Leiomyoma · Menorrhagia, led by 21 companies.

Drug pageEstradiol: every studyMany companies study it; this page follows only the 55 they lead. All 300 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Oct 8, 201255 company-led studies, 1 open or runningNext primary completion: May 31, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novo Nordiskits history only120 open or runningphase 4since Oct 8, 2012Apr 19, 2005none ahead
Bayerits history only100 open or runningphase 4since Sep 12, 2005Sep 9, 2005none ahead
AbbVieits history only80 open or runningphase 3since Feb 17, 2010Feb 17, 2010none ahead
Teva Pharmaceutical Industriesits history only30 open or runningphase 3since Nov 7, 2022Jul 2, 2010none ahead
TherapeuticsMDits history only30 open or runningphase 3since Sep 5, 2013Sep 5, 2013none ahead
Grünenthalits history only20 open or runningphase 1since Nov 9, 2018Nov 9, 2018none ahead
Merckits history only20 open or runningphase 1since Nov 26, 2008Nov 26, 2008none ahead
Renovoits history only20 open or runningphase 3since Jan 24, 2007Jan 24, 2007none ahead
Amneal Pharmaceuticalsits history only10 open or runningphase 3since Jan 28, 2013Jan 28, 2013none ahead
ASCEND Therapeutics10 open or runningphase 4since Sep 8, 2005Sep 8, 2005none ahead

Also a collaborator on its studies: IQVIA Pty, Abbott, Simbec Research, Laboratoires Besins International and Grünenthal.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of ASCEND Therapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 8, 2005First study: phase 4 study in Postmenopausal SymptomsFirst studyNCT00160173 · 221 enrolled · United States

TargetBeta

ESR1 →read by rule
“Estrogen receptor alpha agonist”ChEMBL 37, by rule

Other programs on ESR1

ProgramCompanyFurthest phaseStudies
Ethinyl EstradiolruleJohnson & Johnsonphase 470
FulvestrantruleAstraZenecaphase 430
TamoxifenruleAstraZenecaphase 421
ClomipheneruleHamad Medicalphase 43
vepdegestrantrulePfizerphase 320
camizestrantruleAstraZenecaphase 318
giredestrantHoffmann-La Rochephase 317
HRS-8080Jiangsu HengRui Medicinephase 313
elacestrantruleMenarini Groupphase 312
ImlunestrantruleEli Lillyphase 312
taragarestrantruleInventisBiophase 35
SIM0270ruleSimcere Pharmaceutical Groupphase 35

Studies

The one study ASCEND Therapeutics leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00160173Postmenopausal Symptoms · United States4CompletedSep 6, 2005221

How it is read

Names in the registry

  • “Estradiol”, 7 entries
  • “NOMAC-E2”, 6 entries
  • “estradiol, 25 mcg”, 5 entries
  • “estradiol, 10 mcg”, 4 entries
  • “Zesteem”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.